Quince Therapeutics, Inc. (QNCX)
↓ Download CSV| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -$58.07M | -$57.28M | -$34.62M | -$52.02M | -$90.32M | -$78.89M | -$39.17M | -$12.12M | — |
| Net Income | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -$89.94M | -$76.85M | -$36.98M | -$12.48M | — |
| EPS (Diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | — | — | — | — |
| Total Assets | $93.52M | $114.48M | $167.90M | $103.91M | $133.23M | $189.47M | $124.37M | $72.88M | — |
| Total Liabilities | $129.24M | $84.33M | $82.82M | $3.32M | $14.64M | $17.20M | $8.89M | $1.46M | — |
| Shareholders' Equity | -$35.71M | $30.15M | $85.08M | $100.59M | $118.59M | $172.26M | $115.48M | -$32.63M | -$20.28M |
| Cash & Equivalents | $5.81M | $6.21M | — | — | — | — | $51.21M | $24.87M | — |
| Operating Cash Flow | -$41.42M | -$31.90M | -$18.29M | -$44.04M | -$62.93M | -$50.82M | -$33.28M | -$11.70M | — |
| Capital Expenditures | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K | $52.0K | $55.0K | $212.0K | — |
| Shares Outstanding | 55.73M | 44.00M | 42.97M | 36.14M | 30.07M | 29.54M | 26.87M | 3.41M | — |